Literature DB >> 10810401

Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.

A Oberg1, M Höyhtyä, B Tavelin, R Stenling, G Lindmark.   

Abstract

PURPOSE: We studied whether preoperative serum levels of free MMP-2, the MMP-2/TIMP-2 complex, and total amounts of MMP-9, TIMP-1 and TIMP-2 correlated to the tumor stage and prognosis in colorectal cancer.
METHODS: Samples from 158 patients operated on for colorectal cancer (100 colon, 58 rectum) and samples from 80 healthy blood donors were analyzed using an ELISA technique. One hundred and thirty-three patients were resected for cure, (31, 61, and 41 in Dukes' stages A, B, and C, respectively). At follow-up in January 1998, 44 patients had died from their cancer after a median time 14 months (range 2-55). Fifteen patients died without tumor relapse. Ninety-nine patients were alive after, a median time of 46 months (range 17-68).
RESULTS: Wide, overlapping ranges were observed for all factors both in the patients and in the control group. The patients as compared to the control group had significantly higher levels of free MMP-2 and total amounts of MMP-9, TIMP-1 and TIMP-2, whereas the level of the MMP-2/TIMP-2 complex was significantly lower. TIMP-1 was significantly higher in Dukes' D compared to Dukes' A-C cases; the other factors did not correlate to tumor stage. Elevated TIMP-2 levels (median cut-off limit), only, correlated to worse prognosis when analysed in all patients (p < 0.05). None of the factors (median cut-off limit) correlated to survival in Dukes' A-C patients; analyses based on the upper quartile cut-off limit demonstrated that elevated MMP-2 levels correlated to shorter survival time (p < 0.05).
CONCLUSION: Serum analyses of free MMP-2 the MMP-2/TIMP-2 complex and total amounts of MMP-9, TIMP-1 and TIMP-2 are of limited value for tumor staging and prognosis in colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10810401

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  18 in total

1.  Increased plasma MMP-2 protein expression in lymph node-positive patients with colorectal cancer.

Authors:  Marcus Langenskiöld; Lena Holmdahl; Peter Falk; Marie-Louise Ivarsson
Journal:  Int J Colorectal Dis       Date:  2004-12-08       Impact factor: 2.571

2.  High levels of serum VEGF and TIMP-1 are correlated with colon cancer liver metastasis and intrahepatic recurrence after liver resection.

Authors:  Byung Soh Min; Nam Kyu Kim; Hee Chul Jeong; Hyun Cheol Chung
Journal:  Oncol Lett       Date:  2012-04-23       Impact factor: 2.967

3.  Serum cellular apoptosis susceptibility protein is a potential prognostic marker for metastatic colorectal cancer.

Authors:  Chin-Shaw Stella Tsai; Hung-Chang Chen; Jai-Nien Tung; Shung-Sheng Tsou; Tang-Yi Tsao; Ching-Fong Liao; Ying-Chun Chen; Chi-Yuan Yeh; Kun-Tu Yeh; Ming-Chung Jiang
Journal:  Am J Pathol       Date:  2010-02-11       Impact factor: 4.307

4.  Matrix metalloproteinases in rectal mucosa, tumour and plasma: response after preoperative irradiation.

Authors:  Eva Angenete; Marcus Langenskiöld; Peter Falk; Marie-Louise Ivarsson
Journal:  Int J Colorectal Dis       Date:  2006-11-16       Impact factor: 2.571

5.  The diagnostic value of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) determination in the sera of colorectal adenoma and cancer patients.

Authors:  Barbara Mroczko; Magdalena Groblewska; Bogna Okulczyk; Bogusław Kedra; Maciej Szmitkowski
Journal:  Int J Colorectal Dis       Date:  2010-06-17       Impact factor: 2.571

6.  Levels of Circulating TIMP-2 and MMP2-TIMP2 Complex Are Decreased in Squamous Cervical Carcinoma.

Authors:  Talvensaari-Mattila Anne; Turpeenniemi-Hujanen Taina
Journal:  Obstet Gynecol Int       Date:  2010-06-29

7.  Clinical significance of serum MMP-2 and MMP-7 in patients with ovarian cancer.

Authors:  Ayla Acar; Anil Onan; Ugur Coskun; Aytug Uner; Umit Bagriacik; Funda Atalay; Diclehan Kilic Unsal; Haldun Guner
Journal:  Med Oncol       Date:  2007-12-11       Impact factor: 3.064

8.  Impact of plasma tissue inhibitor of metalloproteinase-1 on long-term survival in patients with gastric cancer.

Authors:  Takaki Yoshikawa; Haruhiko Cho; Akira Tsuburaya; Osamu Kobayashi
Journal:  Gastric Cancer       Date:  2009-04-24       Impact factor: 7.370

9.  Tissue inhibitor of matrix metalloproteinase-2 in nasopharyngeal carcinoma.

Authors:  Amr Ahmed El Badry; Amal Abou El-Fadle; Abdel Latif El-Balshy
Journal:  MedGenMed       Date:  2007-07-03

10.  Balance between activation and inhibition of matrix metalloproteinase-2 (MMP-2) is altered in colorectal tumors compared to normal colonic epithelium.

Authors:  Deborah L Ornstein; Kenneth H Cohn
Journal:  Dig Dis Sci       Date:  2002-08       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.